Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 Jun 2017

Ring Kari L, Yates Melinda S, Schmandt Rosemarie, Onstad Michaela, Zhang Qian, Celestino Joseph, Kwan Suet-Ying, Lu Karen H

Abstract excerpt

OBJECTIVES: The aims of this study were to determine if activating KRas mutation alters estrogen signaling in endometrial cancer (EC) and to explore the potential therapeutic impact of these alterations. METHODS: The Cancer Genome Atlas was queried for changes in estrogen-regulated genes in EC based on KRas mutation status. In vitro studies were conducted to evaluate estrogen receptor α (ERα) phosphorylation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endometrial Neoplasms
Share to Estradiol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Pyridones

Share to Pyrimidinones

Share to Receptors, Progesterone

Source

Open in PubMed Open full text

Identifiers

PMID: 28498246
DOI: 10.1097/IGC.0000000000000960
PMCID: PMC5438270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.PMID 28498246Read ↗

KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.Semantic proximity Read ↗

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.Semantic proximity Read ↗

Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.Semantic proximity Read ↗

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers.Semantic proximity Read ↗

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.Semantic proximity Read ↗

Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.Semantic proximity Read ↗

The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.Semantic proximity Read ↗

KRAS Mutations in Mucinous Lesions of the Uterus.Semantic proximity Read ↗

Endometrial carcinomas with significant mucinous differentiation associated with higher frequency of k-ras mutations: a morphologic and molecular correlation study.Semantic proximity Read ↗

Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium.Semantic proximity Read ↗

Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.Semantic proximity Read ↗

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.